OXFORD UNIVERSITY PRESS

Prostate Cancer (2nd edition)

ISBN : 9780199573936

Price(incl.tax): 
¥1,826
Author: 
Malcolm Mason; Leslie Moffat
Pages
120 Pages
Format
Paperback
Size
130 x 195 mm
Pub date
Jun 2010
Series
Facts
Send mail
Print

Around 32,000 men in the UK are diagnosed with prostate cancer each year. It differs from most other cancers in the body, in that small areas of cancer within the prostate are very common and may not grow or cause any problems for many years. It is often it is diagnosed during a routine checkup so most men that are diagnosed often have no warning signs. About one in three men over the age of 50 have some cancer cells within their prostate and nearly all men over the age of 80 have a small area of prostate cancer. It may cause pain, difficulty in urinating, erectile dysfunction and other symptoms, but early prostate cancer usually causes no symptoms. Since the first edition of this book was published in 2003, there have been several groundbreaking studies completed that have changed the way that certain categories of the disease are treated. This new edition of the book includes sections on radiotherapy, which is now known to be an effective treatment for men with residual prostate cancer after surgery, and a heavily updated chapter on Advanced Disease.

Index: 

1. Introduction
2. How do doctors measure the severity and extent of a prostate cancer?
3. Risks and benefits of screening and radical treatment - a guide
4. Treatment and management options
5. Screening
6. Hormone therapy
7. Locally Advanced Disease
8. Advanced Disease
9. Alternative treatments
10. Chemo prevention and vitamins
11. Clinical Trials
12. Prostate cancer and sex
13. Questions and answers
Glossary
Sources of information

About the author: 

Professor Malcolm Mason is an Oncologist with a special interest in prostate cancer. He has been closely involved in clinical trials in prostate cancer for the Medical Research Council for over 18 years, and he has had a research programme in Cardiff University into this disease since 1997. He qualified in London at St Bartholomew's Hospital, and trained in Oncology at the Royal Marsden Hospital, London. He moved to Cardiff in 1992. He is also past-Chairman of the British Prostate Group. In 2009, Professor Mason was appointed the Chairman of the National cancer Research Institute's Prostate Cancer Clinical Studies Group, the main UK group responsible for developing and overseeing clinical trials in prostate cancer in the UK. ; Mr Leslie Moffat trained in Edinburgh and Glasgow. He published the largest study of LHRH analogues Chairman of Scottish Urological Cancer Audit, the largest of its kind in the world.

The price listed on this page is the recommended retail price for Japan. When a discount is applied, the discounted price is indicated as “Discount price”. Prices are subject to change without notice.